Clevudine

Clevudine

Clevudine is an L-nucleoside pyrimidine analog that is the unnatural -enantiomer of the natural nucleoside -thymidine. It has potent antiviral activity against hepadnaviruses including hepatitis B virus (HBV) in vitro and in vivo. Unlike NAs, clevudine is a pyrimidine analogue that distorts the HBV polymerase active site to noncompetitively inhibit all polymerase functions.From: Current state-of-the-art pharmacotherapy for the management of hepatitis B infection [2019], Kucers’ The Use of Antibiotics [2017], Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: a spotlight on drugs in phase II clinical trials [2022]

Discontinued Hepatitis Agent: Clevudine

View Chapter

Purchase Book

Published in M. Lindsay Grayson, Sara E. Cosgrove, Suzanne M. Crowe, M. Lindsay Grayson, William Hope, James S. McCarthy, John Mills, Johan W. Mouton, David L. Paterson, Kucers’ The Use of Antibiotics, 2017

Ruth Chin, Joseph Torresi, John Mills

In earlier editions of this text, this chapter included a number of clinical trials, the results of which were published between 2004 and 2007. These clinical trials showed that clevudine had activity toward hepatitis B virus, but the studies apparently downplayed or missed some of the drug’s side effects and relatively poor efficacy compared with other drugs.

Current state-of-the-art pharmacotherapy for the management of hepatitis B infection

View Article

Journal Information

Published in Expert Opinion on Pharmacotherapy, 2019

Hans L. Tillmann, Gbeminiyi Samuel

Another L-nucleoside pyrimidine analog, Clevudine, was found to have potent antiviral activity against HBV. 30 mg clevudine daily resulted in a cumulative rate of undetectable HBV DNA of 67–83%. Clevudine use though approved in Korea and the Philippines is limited in others because of myopathy [3,12]. Given its side effect and the many alternative antivirals available, clevudine has not been recommended by any guideline that we are aware of and cannot see a place for it. Its mutation profile also include the ‘YMDD’ motif.

Explore chapters and articles related to this topic

Discontinued Hepatitis Agent: Clevudine

Current state-of-the-art pharmacotherapy for the management of hepatitis B infection